Your browser is no longer supported. Please, upgrade your browser.
Settings
NLTX Neoleukin Therapeutics, Inc. daily Stock Chart
NLTX [NASD]
Neoleukin Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.86 Insider Own22.09% Shs Outstand49.39M Perf Week-9.61%
Market Cap438.98M Forward P/E- EPS next Y-1.10 Insider Trans0.00% Shs Float32.71M Perf Month-9.38%
Income-85.60M PEG- EPS next Q-0.22 Inst Own60.70% Short Float7.82% Perf Quarter-2.90%
Sales- P/S- EPS this Y-91.30% Inst Trans0.20% Short Ratio11.19 Perf Half Y-14.10%
Book/sh2.61 P/B4.11 EPS next Y-23.60% ROA-66.50% Target Price- Perf Year294.12%
Cash/sh3.16 P/C3.39 EPS next 5Y25.20% ROE-72.20% 52W Range2.53 - 18.13 Perf YTD-12.99%
Dividend- P/FCF- EPS past 5Y1.30% ROI- 52W High-40.87% Beta0.96
Dividend %- Quick Ratio20.70 Sales past 5Y- Gross Margin- 52W Low323.72% ATR0.89
Employees36 Current Ratio20.70 Sales Q/Q- Oper. Margin- RSI (14)36.43 Volatility8.70% 7.22%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.74 Prev Close11.63
ShortableYes LT Debt/Eq0.00 EarningsAug 12 AMC Payout- Avg Volume228.76K Price10.72
Recom1.40 SMA20-12.34% SMA50-13.78% SMA200-9.74% Volume170,850 Change-7.82%
Sep-23-20Initiated Robert W. Baird Outperform $25
Jun-18-20Initiated Mizuho Buy $21
Apr-13-20Initiated H.C. Wainwright Buy $22
Mar-16-20Initiated BofA/Merrill Buy $18
Mar-12-20Initiated Canaccord Genuity Buy $20
Feb-18-20Initiated Guggenheim Buy $20
Jan-10-20Initiated Piper Sandler Overweight $20
Oct-20-20 08:00AM  
Oct-14-20 05:05PM  
Oct-13-20 03:06PM  
Sep-23-20 09:33AM  
Sep-15-20 01:11PM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Aug-20-20 01:26PM  
Aug-19-20 12:00PM  
Aug-12-20 04:01PM  
Aug-06-20 08:00AM  
Aug-05-20 08:00AM  
Aug-03-20 10:50AM  
Jul-15-20 07:21AM  
Jul-07-20 07:35AM  
Jul-03-20 12:00PM  
Jul-02-20 12:54PM  
09:00AM  
Jul-01-20 04:01PM  
Jun-24-20 10:24AM  
Jun-22-20 09:05AM  
Jun-19-20 12:49PM  
Jun-15-20 08:00AM  
Jun-01-20 08:00AM  
May-27-20 08:00AM  
May-20-20 08:49AM  
May-15-20 07:00AM  
May-07-20 08:00AM  
May-06-20 04:01PM  
Apr-16-20 04:05PM  
Apr-09-20 08:00AM  
Mar-12-20 04:01PM  
02:30PM  
Mar-05-20 08:00AM  
Feb-25-20 08:00AM  
Feb-24-20 08:00AM  
Feb-06-20 08:00AM  
Jan-23-20 02:22PM  
Jan-21-20 07:22AM  
Dec-20-19 04:01PM  
Dec-17-19 10:26PM  
05:43PM  
04:38PM  
Dec-05-19 08:00AM  
Nov-26-19 08:00AM  
Nov-13-19 09:15AM  
Sep-20-19 11:28AM  
Sep-19-19 08:00AM  
Sep-05-19 04:05PM  
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLC10% OwnerApr 02Buy11.3739,300446,9584,051,045Apr 06 07:04 PM
Redmile Group, LLC10% OwnerApr 02Sale11.319,834111,2144,041,211Apr 06 07:04 PM
Redmile Group, LLC10% OwnerApr 01Buy11.1042,500471,6304,021,579Apr 06 07:04 PM
Redmile Group, LLC10% OwnerApr 01Sale11.089,834108,9404,011,745Apr 06 07:04 PM
Redmile Group, LLC10% OwnerMar 31Buy10.3130,000309,3893,979,079Apr 06 07:04 PM
Redmile Group, LLC10% OwnerMar 30Buy9.9432,500322,9103,949,079Apr 06 07:04 PM
Redmile Group, LLC10% OwnerMar 27Buy9.2150,000460,3953,916,579Apr 06 07:04 PM
DRACHMAN JONATHAN GPresident and CEODec 20Buy8.40119,047999,9952,198,686Dec 20 06:53 PM
BAKER BROS. ADVISORS LPDirectorDec 20Buy8.403,017,54225,347,35312,872,664Dec 20 05:16 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.